Skip to content

Drug interactions

Eliglustat + Pimavanserin

Severity: Major

Eliglustat and Pimavanserin: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Both drugs can prolong the QT interval. Eliglustat is also a CYP2D6 and P-gp inhibitor, and its exposure varies with CYP2D6 status. The combination may increase the risk of ventricular arrhythmia in susceptible patients.

What this interaction means in plain words

Eliglustat and Pimavanserin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Eliglustat belongs to Miscellaneous; Pimavanserin belongs to Central Nervous System.

Evidence level: Low

Why it happens

Additive QT prolongation through effects on cardiac repolarization.

What to do

Avoid the combination in patients with cardiac disease or other QT risk factors. Otherwise obtain a baseline ECG and monitor the QTc.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Eliglustat and Pimavanserin, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Eliglustat with Pimavanserin?

MediHelp rates the interaction as major. Eliglustat and Pimavanserin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both drugs can prolong the QT interval. Eliglustat is also a CYP2D6 and P-gp inhibitor, and its exposure varies with CYP2D6 status. The combination may increase the risk of ventricular arrhythmia in susceptible patients.

How serious is the interaction between Eliglustat and Pimavanserin?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination in patients with cardiac disease or other QT risk factors. Otherwise obtain a baseline ECG and monitor the QTc.

What other medicines interact with Pimavanserin?

MediHelp also lists interactions of Pimavanserin with, for example, Lefamulin, Pimozide, Vandetanib. The full list is on the Pimavanserin page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in